Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats - PubMed (original) (raw)
Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats
Steven Dooley et al. Gastroenterology. 2003 Jul.
Abstract
Background & aims: Numerous studies implicate transforming growth factor (TGF)-beta signaling in liver fibrogenesis. To perturb the TGF-beta pathway during this process, we overexpressed Smad7, an intracellular antagonist of TGF-beta signaling, in vivo and in primary-cultured hepatic stellate cells (HSCs).
Methods: Ligation of the common bile duct (BDL) was used to induce liver fibrosis in rats. Animals received injections of an adenovirus carrying Smad7 cDNA into the portal vein during surgery and via the tail vein at later stages. The effect of Smad7 on TGF-beta signaling and activation of HSC was further analyzed in primary-cultured cells.
Results: Smad7-overexpressing BDL rats displayed reduced collagen and alpha-SMA expression and reduced hydroxyproline content in the liver, when compared with animals administered AdLacZ. Such a beneficial effect was also observed when Smad7 was expressed in animals with established fibrosis. Accordingly, Smad7 arrested transdifferentiation of primary-cultured HSCs. AdSmad7 infected cells remained in a quiescent stage and retained storage of vitamin A droplets. Smad7 expression totally blocked TGF-beta signal transduction, shown by inhibiting Smad2/3 phosphorylation, nuclear translocation of activated Smad complexes, and activation of (CAGA)(9)-MLP-Luc, resulting in decreased collagen I expression. Smad7 also abrogated TGF-beta-dependent proliferation inhibition of HSC. Smad7 did not decrease expression of alpha-SMA, but immunofluorescent staining with anti alpha-SMA antibodies displayed destruction of the fibrillar organization of the actin cytoskeleton.
Conclusions: In summary, gene transfer of Smad7 inhibits experimental fibrogenesis in vivo. Studies with isolated HSC suggest that the underlying mechanisms involve inhibition of TGF-beta signaling and HSC transdifferentiation.
Similar articles
- Liuweiwuling tablets attenuate BDL-induced hepatic fibrosis via modulation of TGF-β/Smad and NF-κB signaling pathways.
Liu H, Dong F, Li G, Niu M, Zhang C, Han Y, He L, Yin P, Wang B, Sang X, Li R, Wang J, Bai Z, Xiao X. Liu H, et al. J Ethnopharmacol. 2018 Jan 10;210:232-241. doi: 10.1016/j.jep.2017.08.029. Epub 2017 Aug 31. J Ethnopharmacol. 2018. PMID: 28864168 - Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts.
Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Dooley S, et al. Hepatology. 2000 May;31(5):1094-106. doi: 10.1053/he.2000.6126. Hepatology. 2000. PMID: 10796885 - Transdifferentiation-dependent expression of alpha-SMA in hepatic stellate cells does not involve TGF-beta pathways leading to coinduction of collagen type I and thrombospondin-2.
Lindert S, Wickert L, Sawitza I, Wiercinska E, Gressner AM, Dooley S, Breitkopf K. Lindert S, et al. Matrix Biol. 2005 May;24(3):198-207. doi: 10.1016/j.matbio.2005.03.003. Matrix Biol. 2005. PMID: 15905080 - Anti-TGF-beta strategies for the treatment of chronic liver disease.
Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Breitkopf K, et al. Alcohol Clin Exp Res. 2005 Nov;29(11 Suppl):121S-131S. doi: 10.1097/01.alc.0000189284.98684.22. Alcohol Clin Exp Res. 2005. PMID: 16344596 Review. - The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis.
Wells RG. Wells RG. J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S158-61. doi: 10.1097/01.mcg.0000155516.02468.0f. J Clin Gastroenterol. 2005. PMID: 15758652 Review.
Cited by
- Comprehensive Insights into Keloid Pathogenesis and Advanced Therapeutic Strategies.
Kim HJ, Kim YH. Kim HJ, et al. Int J Mol Sci. 2024 Aug 12;25(16):8776. doi: 10.3390/ijms25168776. Int J Mol Sci. 2024. PMID: 39201463 Free PMC article. Review. - Ursodeoxycholic acid ameliorates erectile dysfunction and corporal fibrosis in diabetic rats by inhibiting the TGF-β1/Smad2 pathway.
Cavusoglu Nalbantoglu I, Sevgi S, Kerimoglu G, Kadıoglu Duman M, Kalyoncu NI. Cavusoglu Nalbantoglu I, et al. Int J Impot Res. 2024 Mar 7. doi: 10.1038/s41443-024-00868-9. Online ahead of print. Int J Impot Res. 2024. PMID: 38454160 - The Role of TGF-β/SMAD Signaling in Hepatocellular Carcinoma: from Mechanism to Therapy and Prognosis.
Xin X, Cheng X, Zeng F, Xu Q, Hou L. Xin X, et al. Int J Biol Sci. 2024 Feb 4;20(4):1436-1451. doi: 10.7150/ijbs.89568. eCollection 2024. Int J Biol Sci. 2024. PMID: 38385079 Free PMC article. Review. - Application of the Human Amniotic Membrane as an Adjuvant Therapy for the Treatment of Hepatocellular Carcinoma.
Abou-Shanab AM, Gaser OA, Salah RA, El-Badri N. Abou-Shanab AM, et al. Adv Exp Med Biol. 2024;1470:129-146. doi: 10.1007/5584_2023_792. Adv Exp Med Biol. 2024. PMID: 38036871 Review. - Cellular heterogeneity and plasticity during NAFLD progression.
Park HJ, Choi J, Kim H, Yang DY, An TH, Lee EW, Han BS, Lee SC, Kim WK, Bae KH, Oh KJ. Park HJ, et al. Front Mol Biosci. 2023 Aug 11;10:1221669. doi: 10.3389/fmolb.2023.1221669. eCollection 2023. Front Mol Biosci. 2023. PMID: 37635938 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical